Sector Expert: Michael Becker

Relmada Therapeutics Inc.

Image: Michael Becker

Michael Becker joined Relmada Therapeutics Inc. in November 2014, and currently serves as the company’s vice president of finance and corporate development. Mr. Becker brings more than 20 years of experience as a C-level industry executive and Wall Street securities analyst. Most recently, he was founder and president of the consulting firm MDB Communications LLC. In this position, he acted as a strategic advisor and partner servicing the life sciences industry by providing a full range of investor relations and public relations services to enhance client visibility and branding. Mr. Becker previously served as president, chief executive officer and member of the board of directors for publicly traded biotechnology companies including commercial-stage Cytogen Corp. (acquired by EUSA Pharma). He held positions of increasing responsibility prior to being appointed president and CEO of Cytogen in 2002, including vice president of business development, industry and investor relations, and CEO of AxCell Biosciences, a subsidiary of Cytogen. Prior to his industry career, Mr. Becker spent nine years in the financial services industry, which includes positions at Wayne Hummer Investments LLC, Kidder, Peabody & Co., Gruntal & Co., and Kemper Securities. He completed coursework in political science at DePaul University, and received an associate of science degree from the Art Institute of Pittsburgh.

Recent Interviews

Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse (4/20/16)

To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. In this interview with The Life Sciences Report, Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.

Due to permission requirements, not all quotes are shown.